SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

tenapanor

ARDX·Ardelyx, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (IBS-C and hyperphosphatemia); Phase 3 for CIC
Time to market
Already on the market for IBS-C (since 2021 launch) and hyperphosphatemia (since 2023 launch). CIC label expansion would be the next milestone, with data expected H2 2027 and potential FDA filing in 2028.
Why 4/10
Tenapanor is already approved and commercialized in two indications with no pending regulatory decision. The next hard catalyst is the Phase 3 ACCEL CIC topline readout, expected in H2 2027 (more than 12 months away). Since there is no dated binary catalyst within ~12 months, the impact score is capped at 5. The drug is the sole revenue driver for Ardelyx, but the defining binary events (initial approvals) have already passed, and commercial execution is a gradual, non-binary driver.
Actionable Insight NEUTRAL

Tenapanor is a mature commercial asset with no near-term binary catalyst. Watch the Q4 2026 earnings (expected early 2027) for whether IBSRELA revenue growth stabilizes or continues decelerating. The Phase 3 ACCEL CIC readout in H2 2027 is the next major value-inflection point, but it is over 12 months away. In the meantime, payor access dynamics and prescription trends will drive the stock more than any single event.

Price Chart

Loading chart...

Executive Summary

Tenapanor is Ardelyx's only commercial product, sold under two brands: IBSRELA for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for hyperphosphatemia in dialysis patients. It is a first-in-class NHE3 inhibitor that works locally in the gut. In Q3 2026, the two brands generated $125.5M in combined product revenue (+19% YoY), with IBSRELA contributing $96.3M (+23%) and XPHOZAH $29.2M (+7%). The company is nearing profitability (net loss narrowed to $0.7M) and has $285M cash. The next major catalyst is the Phase 3 ACCEL trial readout for chronic idiopathic constipation, expected in H2 2027, which is more than 12 months away. Analyst consensus is strongly bullish (16 of 17 analysts rate Buy/Strong Buy) with a mean price target of $12.80, implying 289% upside from the current $3.29 price.

How It Works

Tenapanor is a pill that blocks a protein called NHE3 in the gut. By blocking this sodium 'pump,' it keeps more water in the intestines, which softens stool and makes bowel movements easier (used for IBS-C). It also reduces how much phosphate the body absorbs from food, which helps dialysis patients with high phosphate levels (hyperphosphatemia).

Trial Status

Tenapanor is already FDA-approved in two indications: IBSRELA for IBS-C (approved September 2019) and XPHOZAH for hyperphosphatemia in dialysis patients (approved October 2023). Ardelyx completed enrollment ahead of schedule in the Phase 3 ACCEL trial evaluating tenapanor for chronic idiopathic constipation (CIC), with topline data expected in the second half of 2027. Pediatric trials in IBS-C have completed: a Phase 3 in adolescents 12-18 years and a Phase 2 in children 6-12 years.

The Two-Sided Case

▲ Bull Case6
IBSRELA revenue grew 23% YoY to $96.3M in Q3 2026, with full-year guidance of $350-370M, showing strong commercial execution in a $4.5B+ IBS-C market
Analyst consensus is heavily bullish: 16 of 17 analysts rate Buy or Strong Buy, with a mean price target of $12.80 (289% upside from $3.29)
New USPTO patent covering commercial formulations extends IP protection to December 2041, providing long-term exclusivity
Rubric Capital Management doubled its position in Q2 2026 to $82.6M, and Citigroup doubled in Q3 2026, signaling institutional confidence
Company is approaching profitability with net loss narrowing to just $0.7M in Q3 2026, and $285M cash supports pipeline investment
Phase 3 ACCEL trial for CIC (a larger addressable market than IBS-C) is fully enrolled ahead of schedule, offering a label-expansion opportunity
▼ Bear Case7
Revenue growth is decelerating: from 58% YoY in Q1 2026 to 33% in Q2 to 23% in Q3, and XPHOZAH growth slowed to just 7% in Q3
Multiple insiders sold shares on August 21, 2026 at ~$3.86, including the CEO (Michael Raab sold ~$168K), CFO, and other officers, which may signal limited near-term upside conviction
Several prominent hedge funds exited or severely trimmed positions in Q2 2026: Point72 exited entirely, Citadel trimmed 70%, Marshall Wace cut 96.5%, and D.E. Shaw cut 95.8%
The company remains unprofitable with a cumulative net loss of $55.1M in the first nine months of 2026
IBSRELA faces strong competition from established brands Linzess (linaclotide, AbbVie), Trulance (plecanatide, Salix), and generic lubiprostone
Payer access barriers and prior authorization requirements continue to slow new patient starts, as noted in Q2 guidance adjustments
The next major catalyst (ACCEL CIC readout) is not expected until H2 2027, leaving a long period without a binary event

Upcoming Catalysts

  • Phase 3 ACCEL CIC topline data (H2 2027)
  • Pediatric IBS-C trial data readouts
  • RDX10531 next-generation NHE3 inhibitor preclinical/early clinical updates
  • Quarterly earnings reports tracking revenue growth trajectory

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Ardelyx, Inc. PRESS-RELEASE ARDX ·Originating report

Sources · 12

Hover a chip for the title
1 drugs.com2 drugs.com3 ir.ardelyx.com4 markets.businessinsider.com5 biospace.com6 last10k.com7 sec.gov8 en.wikipedia.org9 drugs.com10 drugs.com11 ardelyx.com12 eureka.patsnap.com